אודות בית הספר


בית הספר לרוקחות באוניברסיטה העברית, מהמובילים בתחומו בעולם בהכשרת רוקחים ובמחקר בסיסי במדעי התרופה, הוקם בשנת 1953.
בית הספר מכשיר את בוגריו לעסוק במקצוע הרוקחות, מקנה להם בסיס מדעי ומקצועי, ומציע לימודים גבוהים בפרמקולוגיה, כימיה תרופתית ומדעי הרוקחות (M.Sc. ו- Ph.D.), וכן לימודים לתואר דוקטור ברוקחות קלינית (Pharm.D.).
בוגרי בית הספר משתלבים ברוקחות קהילתית (בתי מרקחת קהילתיים, פרטיים ומוסדיים), ברוקחות קלינית (בתי חולים וקופות החולים), בתעשיית התרופות, בתעשיות הביולוגיות, הכימיות והביוטכנולוגיות, במינהל רוקחי ובמוסדות מדע ומחקר בארץ ובחו"ל.
בבית הספר מתנהל מחקר מדעי רחב היקף בתחומי מדעי התרופה ומדעי החיים, עשרות מאמרים מתפרסמים מדי שנה בעיתונות המובילה בעולם המדע.
בית הספר לרוקחות הוא חלק מהפקולטה לרפואה, נמצא בקמפוס עין כרם של האוניברסיטה העברית ופועל בשיתוף פעולה הדוק עם רופאים וחוקרים מביה"ח הדסה.

  קרא עוד >>  

בחזית המחקר

award_school_of_pharmacy.jpg

מענק ממשרד המדע והטכנולוגיה הישראלי לחוקרי ביה"ס

קרא עוד

Significant Achievement for our School! 8 Researchers were awarded the highly competitive Science Upfront grant from the Israel Ministry of Science and Technology! Notably 4 of the awardees are young PIs that join our institute in the past 3 years! Congratulations to Boaz Tirosh, Eylon Yavin, Ofra Benny, Reuven Reich, Raphael Benhamou, Gali Umschweif, Katy Margulis and Tawfeeq Shekh Ahmad!

 

 

 

קראו פחות
למחקרים נוספים >>

פרסומים אחרונים

Pier Giorgio Puzzovio, Thayse R Brüggemann, Hadas Pahima, David Mankuta, Bruce D Levy, ו Francesca Levi-Schaffer. 2022. “Cromolyn Sodium differentially regulates human mast cell and mouse leukocyte responses to control allergic inflammation.” Pharmacological research, Pp. 106172. Abstract
BACKGROUND: Cromolyn Sodium (CS) has been used in the past as an anti-allergy drug owing to its mast cell (MC) stabilizing properties that impair histamine release. However, additional mechanisms for its clinical actions are likely and might help to identify new roles for MCs and leukocytes in regulating inflammation. Here, using human cord blood-derived MCs (CBMCs), murine bone marrow-derived MCs (BMMCs) and eosinophils (BMEos), and in vivo mouse models of allergic inflammation (AI), additional actions of CS on MCs were determined. METHODS: The in vitro effects of CS on IgE-activated human and mouse MCs were assessed by measuring the levels of pro-inflammatory (tryptase, LTC(4), IL-8, CD48) and pro-resolution effectors (IL-10, CD300a, Annexin A1) before and after CS treatment. The in vivo effects of daily CS injections on parameters of inflammation were assessed using mouse models of allergic peritonitis (AP) (Ovalbumin/Alum- or Ovalbumin/S. aureus enterotoxin B) and allergic airways inflammation (AAI) (house dust mite (HDM)). RESULTS: In vitro, CS did not affect pro-inflammatory effectors but significantly increased the anti-inflammatory/pro-resolution CD300a levels and IL-10 release from IgE-activated CBMCs. BMMCs were not affected by CS. In vivo, CS injections decreased total cell and Eos numbers in the peritoneal cavity in the AP models and bronchoalveolar lavage and lungs in the AAI model. CS reduced EPX release from PAF-activated BMEos in vitro, possibly explaining the in vivo findings. CONCLUSION: Together, these results demonstrate immunomodulatory actions for CS in AI that are broader than only MC stabilization.
Leslie Rebibo, Marina Frušić-Zlotkin, Ron Ofri, Taher Nassar, ו Simon Benita. 2022. “The dose-dependent effect of a stabilized cannabidiol nanoemulsion on ocular surface inflammation and intraocular pressure.” International journal of pharmaceutics, 617, Pp. 121627. Abstract
Cannabidiol (CBD) is a phytocannabinoid that has a great clinical therapeutic potential. Few studies have been published on its efficacy in ocular inflammations while its impact on intraocular pressure (IOP), a major risk factor for glaucoma, remains unclear. Moreover, due to its lability and high lipophilicity, its formulation within a prolonged stable topical ophthalmic solution or emulsion able to penetrate the highly selective corneal barrier is challenging. Therefore, various CBD nanoemulsions (NEs) were designed and evaluated for stability in accelerated conditions. Further, the optimal formulation was tested on a murine LPS-induced keratitis inflammation model. Lastly, increasing CBD concentrations were topically applied, for two weeks, on mice eyes, for IOP measurement. CBD NEs exhibited optimal physicochemical characteristics for ocular delivery. A specific antioxidant was required to obtain the stable, final, formulation. In vivo, 0.4 to 1.6% CBD w/v reduced the levels of key inflammatory cytokines, depending on the concentration applied. These concentrations decreased or did not affect the IOP. Our results showed that a well-designed CBD ocular dosage form can be stabilized for an extended shelf life. Furthermore, the significant decrease in inflammatory cytokines levels could be exploited, provided that an adequate therapeutic dosage regimen is identified in humans.
Tal Israeli, Yael Riahi, Perla Garzon, Ruy Andrade Louzada, Joao Pedro Werneck-de-Castro, Manuel Blandino-Rosano, Roni Yeroslaviz-Stolper, Liat Kadosh, Sharona Tornovsky-Babeay, Gilad Hacker, Nitzan Israeli, Orly Agmon, Boaz Tirosh, Erol Cerasi, Ernesto Bernal-Mizrachi, ו Gil Leibowitz. 2022. “Nutrient Sensor mTORC1 Regulates Insulin Secretion by Modulating $\beta$-Cell Autophagy.” Diabetes, 71, 3, Pp. 453–469. Abstract
The dynamic regulation of autophagy in $\beta$-cells by cycles of fasting-feeding and its effects on insulin secretion are unknown. In $\beta$-cells, mechanistic target of rapamycin complex 1 (mTORC1) is inhibited while fasting and is rapidly stimulated during refeeding by a single amino acid, leucine, and glucose. Stimulation of mTORC1 by nutrients inhibited the autophagy initiator ULK1 and the transcription factor TFEB, thereby preventing autophagy when $\beta$-cells were continuously exposed to nutrients. Inhibition of mTORC1 by Raptor knockout mimicked the effects of fasting and stimulated autophagy while inhibiting insulin secretion, whereas moderate inhibition of autophagy under these conditions rescued insulin secretion. These results show that mTORC1 regulates insulin secretion through modulation of autophagy under different nutritional situations. In the fasting state, autophagy is regulated in an mTORC1-dependent manner, and its stimulation is required to keep insulin levels low, thereby preventing hypoglycemia. Reciprocally, stimulation of mTORC1 by elevated leucine and glucose, which is common in obesity, may promote hyperinsulinemia by inhibiting autophagy.
לרשימה המלאה >>